RxDoctor Payments DataLook up a doctor →

Alexander Swan, MD

Nephrology · Brooklyn, NYNPI 1346218856

Payments from drug & device makers

$171,559in general payments, 2019–2025

Across 2,305 payments — averaging $74.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • AstraZeneca$36K
  • Bayer$29K
  • Amgen$26K
  • OPKO Pharmaceuticals, LLC$15K
  • Mallinckrodt Hospital Products Inc.$6K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$11,7237%
  • Speaking & faculty fees$118,44269%
  • Travel & lodging$9,3045%
  • Food & beverage$31,48218%
  • Education$6090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)444$39,380
AstraZeneca299$35,656
Bayer54$29,171
Amgen(2 entities)344$25,860
OPKO Pharmaceuticals, LLC90$14,927
Mallinckrodt Hospital Products Inc.13$6,051
Phathom Pharmaceuticals, Inc.35$2,661
Calliditas Therapeutics US Inc.12$2,594
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC147$1,835
Biohaven Pharmaceuticals, Inc.13$1,376
Otsuka America Pharmaceutical, Inc.92$1,150
Novo Nordisk85$1,112
ANI Pharmaceuticals, Inc.70$819
Lilly USA, LLC73$818
Teva Pharmaceuticals USA, Inc.27$688
Amarin Pharma, Inc.58$663
Boehringer Ingelheim46$642
Novartis42$605
GSK21$481
Vifor Pharma, Inc.31$430
Ardelyx, Inc.20$411
Sanofi-aventis U.S. LLC25$335
Johnson & Johnson21$309
Esperion Therapeutics, Inc.27$288
Axsome Therapeutics, Inc.19$257
Redhill Biopharma Inc.19$217
Merck16$214
Medtronic(2 entities)7$199
Takeda Pharmaceuticals U.S.A., Inc.14$196
Kowa Pharmaceuticals America, Inc.13$174
Philips North America LLC3$139
Bard Peripheral Vascular, Inc.1$125
Lundbeck LLC9$123
Pfizer8$122
Fresenius USA Marketing, Inc.8$117
Neurocrine Biosciences, Inc.7$114
Ironwood Pharmaceuticals, Inc9$114
Abbott6$106
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$98
Travere Therapeutics, Inc.8$95
Genentech USA, Inc.7$88
Regeneron Healthcare Solutions, Inc.7$83
Endo Pharmaceuticals Inc.6$82
Akebia Therapeutics Inc4$67
Daiichi Sankyo Inc.5$66
Insulet Corporation3$51
Dexcom, Inc.3$50
Biohaven Pharmaceutical Holding Company Ltd.3$46
Renalytix AI, Inc.3$45
Scpharmaceuticals Inc.2$39
Arbor Pharmaceuticals, Inc.3$36
Azurity Pharmaceuticals, Inc.2$33
Mallinckrodt Enterprises LLC2$23
Exact Sciences1$19
Vanda Pharmaceuticals Inc.1$19
Avvisto Therapeutics, LLC1$17
Shield Therapeutics Inc1$17
Ultragenyx Pharmaceutical Inc.1$15
Kyowa Kirin, Inc.1$15
Intra-sana Laboratories1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,559 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$210,294
Medicare patients
207
Services billed
1,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase25$1,415,954
OzempicSemaglutide480$711,422
FarxigaDapagliflozin Propanediol543$657,034
RayaldeeCalcifediol201$284,176
MounjaroTirzepatide221$251,521
Repatha SureclickEvolocumab202$249,397
KerendiaFinerenone201$245,289
TrulicityDulaglutide125$226,156
JanuviaSitagliptin Phosphate199$224,286
Repatha PushtronexEvolocumab169$211,347
ProliaDenosumab123$207,799
VraylarCariprazine Hcl129$198,164
Diclofenac Sodium315$192,539
LinzessLinaclotide204$189,846
TradjentaLinagliptin164$175,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Prolia$25,860$1,623,753148 claims
AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Brilinta$35,656$943,714769 claims
Novo NordiskOzempic, Rybelsus$1,112$864,514590 claims
Lilly USA, LLCMounjaro, Trulicity$818$477,676346 claims
AbbVieVraylar, Linzess, Creon$39,380$419,339344 claims
MerckJanuvia, Janumet Xr, Janumet$214$384,504349 claims
Boehringer IngelheimTradjenta, Jardiance, Jentadueto Xr$642$287,632249 claims
OPKO Pharmaceuticals, LLCRayaldee$14,927$284,176201 claims
BayerKerendia$29,171$245,289201 claims
PfizerEliquis, Nurtec Odt$122$181,483148 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,835$142,67656 claims
Phathom Pharmaceuticals, Inc.Voquezna$2,661$93,73172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.

Other nephrology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →